- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02201303
Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression
perjantai 5. toukokuuta 2017 päivittänyt: GlaxoSmithKline
A Single-Center In Vitro Study to Evaluate GSK1325756 Inhibition of CD11b Cell Surface Expression in Healthy Adults and Respiratory Syncytial Virus-Infected Children <2 Years (200591)
This study is to determine danirixin (GSK1325756) concentrations required to inhibit neutrophil activation in blood obtained from Respiratory Syncytial Virus (RSV)-infected children <2 years and healthy adults.
The study will evaluate differences in neutrophil activation between RSV-infected children <2 years and healthy adults with escalating concentrations of Chemokine (C-X-C motif) Ligand 1 (CXCL1) and danirixin to determine if RSV-infected children and adult neutrophils are similarly activated by CXCL1 and inhibited by danirixin.
This study will guide dose prediction to inhibit specific percentages of neutrophils in future pediatric RSV-infection studies.
This single-center, in vitro study will consist of 2 parts.
Approximately 24 subjects will be enrolled, including 12 healthy adults and 12 RSV-infected children <2 years.
Tutkimuksen yleiskatsaus
Tila
Valmis
Interventio / Hoito
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
40
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
New York
-
Syracuse, New York, Yhdysvallat, 13210
- GSK Investigational Site
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
Ei vanhempi kuin 64 vuotta (Lapsi, Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Joo
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
Inclusion Criteria:
Healthy Adults
- Male/females aged between 18 and 64 years of age inclusive, at the time of signing the informed consent
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history and physical examination. A subject with a clinical abnormality parameter(s) which is not specifically listed in the inclusion or exclusion criteria, may be included only if the Investigator in consultation with the GSK Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Body weight >= 45 kilograms (kg) and body mass index (BMI) within the range 18.5-32 kg/meter^2 (inclusive).
- A female subject is eligible to participate if she is not known to be pregnant by history or delivered within the past 3 months.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
RSV Infected Children
- Male/females aged <2 years, at the time of parent(s)/legal guardian(s) signing the informed consent.
- Healthy, except for current RSV-infection, as determined by a responsible and experienced physician, based on a medical evaluation including medical history and physical examination. A subject with a clinical abnormality parameter(s) which is not specifically listed in the inclusion or exclusion criteria, may be included only if the Investigator in consultation with the GSK Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Body weight >= 3.5 kg
- Documented RSV-infection, either by RSV-antigen or RSV-PCR
- RSV-infection clinical symptom onset within 5 days of blood draw based on parent(s)/guardian(s) history.
- Parent(s)/legal guardian(s) of child capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Exclusion Criteria:
Healthy Adults
- Any clinical infection within the past 14 days per subject's history.
- Acute or chronic infectious/inflammatory diseases by history, including but not limited to, hepatitis B, hepatitis C, human immuno virus (HIV), inflammatory bowel disease, liver / biliary disease, pancreatitis, arthritis.
- Receiving systemic anti-inflammatory or immune modulating medications, including but not limited to, non-steroidal anti-inflammatory (NSAIDS) and glucocorticoids, within the past 14 days. All other medications are permitted.
- Any alcoholic beverage within 24 hours of blood collection and history of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram (g) of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
- Current smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
- Strenuous exercise within 48 hours prior to the blood collection.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to signing the informed consent in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
RSV Infected Children
- A Child in Care: A child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. A child in care can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. A child in care does not include a child who is adopted or has an appointed legal guardian.
- Any clinical infection, besides current RSV infection, within the past 14 days per subject's history
- Acute or chronic infectious/inflammatory diseases by history, including but not limited to, hepatitis B, hepatitis C, HIV, liver / biliary disease, pancreatitis
- Receiving systemic anti-inflammatory or immune modulating medications, including but not limited to, NSAIDS and glucocorticoids, within the past 14 days. All other medications are permitted.
- Past medical history including prematurity <37 weeks, congenital heart disease, chronic lung disease, or immunodeficiency.
- Where participation in the study would result in withdrawal of blood or blood products in excess of 2 mL/kg for 24 hours before or after the study period.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to parent(s)/guardian(s) signing the informed consent in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Ei satunnaistettu
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Part 1
Blood sample will be collected from the RSV-infected children <2 years and healthy adults participants.
Escalating concentrations of CXCL1 will be added to whole blood in vitro and CD11b up regulation on peripheral blood neutrophils will be analyzed
|
Escalating concentrations of CXCL1 will be added to whole blood in vitro.
A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
|
Kokeellinen: Part 2
Blood sample will be collected from the RSV-infected children <2 years and healthy adults participants.
Escalating concentrations of danirixin will be added to whole blood in vitro with a fixed concentration of CXCL1 to determine inhibition of CD11b expression on peripheral blood neutrophils
|
Escalating concentrations of CXCL1 will be added to whole blood in vitro.
A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
Powdered form for in-vitro administration to blood sample
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Percent inhibition of Chemokine Ligand (CXCL1)-induced Cluster of Differentiation 11b expression on peripheral blood neutrophils in RSV-infected children <2 years and healthy adults after in vitro incubation with escalating concentrations of danirixin
Aikaikkuna: Day 1
|
Blood (1.5 milliliter [mL]) will be collected from a peripheral vein via indwelling catheter or direct venepuncture.
Escalating concentrations of danirixin (0.03-100 micromoles) will be added to whole blood in vitro with a fixed concentration of CXCL1 to determine inhibition of Cluster of Differentiation 11b (CD11b) expression on peripheral blood neutrophils analyzed by Fluorescence-Activated Cell sorting (FACs).
|
Day 1
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
CD11b upregulation on peripheral blood neutrophils in RSV-infected children <2 years and healthy adults after in vitro incubation with escalating concentrations of CXCL1
Aikaikkuna: Day 1
|
Blood (1.0 mL) will be collected from a peripheral vein via indwelling catheter or direct venepuncture.
Escalating concentrations of CXCL1 will be added to whole blood in vitro and CD11b upregulation on peripheral blood neutrophils will be analyzed by FACS
|
Day 1
|
Differences in percent inhibition of CXCL1-induced CD11b expression on peripheral blood neutrophils in RSV-infected children <2 years and healthy adults after in vitro incubation with escalating concentrations of danirixin
Aikaikkuna: Day 1
|
Inhibition of CD11b upregulation will be evaluated to determine if there is a similar concentration-response relationship between healthy adults and RSV-infected children
|
Day 1
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Maanantai 13. tammikuuta 2014
Ensisijainen valmistuminen (Todellinen)
Torstai 2. heinäkuuta 2015
Opintojen valmistuminen (Todellinen)
Torstai 2. heinäkuuta 2015
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Torstai 9. tammikuuta 2014
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Torstai 24. heinäkuuta 2014
Ensimmäinen Lähetetty (Arvio)
Maanantai 28. heinäkuuta 2014
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Tiistai 9. toukokuuta 2017
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Perjantai 5. toukokuuta 2017
Viimeksi vahvistettu
Maanantai 1. toukokuuta 2017
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 200591
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Infektiot, Respiratory Syncytial Virus
-
PfizerValmisRESPIRATORY SYNCYTIAL VIRUS (RSV)Yhdysvallat
-
Biota Pharma Europe LimitedValmisRespiratory Syncytial Virus (RSV) -infektioYhdistynyt kuningaskunta
-
PfizerValmisRESPIRATORY SYNCYTIAL VIRUS (RSV)Yhdysvallat
-
AblynxPeruutettuRespiratory Syncytial Virus alempien hengitysteiden infektioBelgia, Espanja, Australia
-
AblynxValmisRespiratory Syncytial Virus alempien hengitysteiden infektioBelgia, Unkari, Israel, Espanja, Viro, Filippiinit, Thaimaa, Bulgaria, Puola, Saksa, Chile, Kolumbia, Kroatia, Tšekki, Latvia, Malesia, Slovakia
-
AblynxLopetettuRespiratory Syncytial Virus alempien hengitysteiden infektioJapani
-
GlaxoSmithKlineValmisInfektiot, Respiratory Syncytial VirusKanada
-
NovavaxValmisRespiratory Synctial VirusKanada
-
Enanta Pharmaceuticals, IncRekrytointiRespiratory Syncytal Virus (RSV)Yhdysvallat, Espanja, Israel, Australia, Saksa, Korean tasavalta, Taiwan, Yhdistynyt kuningaskunta, Argentiina, Brasilia, Uusi Seelanti, Puola, Romania, Etelä-Afrikka, Meksiko
-
NovavaxValmisRespiratory Syncytal Virus (RSV)Yhdysvallat
Kliiniset tutkimukset CXCL1
-
Hospices Civils de LyonEi vielä rekrytointiaX-Linked Hypofosfatemic Rickets